Skip to content

Clinical study on the effect of Li-Ankang hemodialysis concentrated powder on the long-term prognosis of hemodialysis patients

Clinical study on the effect of Li-Ankang hemodialysis concentrated powder on the long-term prognosis of hemodialysis patients

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063767
Enrollment
Unknown
Registered
2022-09-16
Start date
2022-09-19
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complication of hemodialysis

Interventions

Experimental group:Beijing li'ankang hemodialysis concentrated powder
Control group:Hebei ziweishan hemodialysis concentrated powder

Sponsors

Wuhan First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. For maintenance patients with stable chronic renal failure, dialysis treatment should be given three times a week, not less than four hours each time, for at least three months; 2. There is no gender limit, and the age is greater than or equal to 18 years old and less than 80 years old; 3. The subject agrees to participate in this trial and signs an informed consent form; 4. Able to abide by the research procedures stipulated in the protocol; 5. Voluntarily participate and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Subjects who are pregnant, breast-feeding or have pregnancy plans; 2. Subjects with severe anemia (hemoglobin less than 60 g/L), severe infection, tumor, and active bleeding; 3. Subjects with severe liver, heart, lung and other diseases; 4. Subjects with mental illness or medical history; 5. Subjects who have participated in other clinical trials within one month before the start of this trial; 6. Subjects with severe hypotension, allergies, or insufficient dialysis due to physical reasons; 7. Subjects judged by the researcher to be unsuitable for this test; Note: Women of childbearing age who are judged by the researcher to undergo a pregnancy test can be enrolled after a negative result is confirmed.

Design outcomes

Primary

MeasureTime frame
Calcitonin;Serum total calcium;Serum ionized calcium;C-reactive protein;Parathyroid hormone;Serum pH;

Secondary

MeasureTime frame
Serum phosphorus;HCO3- or TCO2 concentration;Serum advanced glycation end products (AGEs);routine blood test;electrolyte;blood sugar;liver function;renal function;B-ultrasound detection (including parathyroid gland, heart, neck blood vessels and lower limb blood vessels);Lung X-ray;electrocardiogram;

Countries

China

Contacts

Public ContactXiong Fei

Wuhan First Hospital

hubeilhliuhong@163.com+86 15871701476

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026